• 1
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 10511062.
  • 2
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994; 331: 896903.
  • 3
    Bishop JF, Matthews JP, Young GAR, Bradstock K, Lowenthal R, on behalf of the ALSG. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma. 1998; 28: 315327.
  • 4
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998; 92: 23222333.
  • 5
    Wahlin A, Hornsten P, Jonsson H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol. 1991; 46: 240247.
  • 6
    The Toronto Leukemia Study Group. Results of chemotherapy for unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results. Lancet. 1986; 1: 786788.
  • 7
    Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21: 46424649.
  • 8
    Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 20612067.
  • 9
    Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia. 2000; 14: 480487.
  • 10
    Estey E. How I treat older patients with AML. Blood. 2000; 96: 16701673.
  • 11
    de Lima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 1996; 93: 8993.
  • 12
    Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990; 8: 272279.
  • 13
    Taylor PRA, Reid MM, Stark AN, Brown N, Hamilton PJ, Proctor SJ. De novo acute myeloid leukemia in patients over 55-years-old: a population based study of incidences, treatment and outcome. Leukemia. 1995; 9: 231237.
  • 14
    Goldstone AH, Burnett A, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 13021311.
  • 15
    Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002; 16: 16271636.
  • 16
    Burnett A, Milligan D, Prentice AG, Goldstone AH, McMullin M, Wheatley K. Low dose ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy. Blood. 2004; 104: 249a.
  • 17
    Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999; 17: 35693576.
  • 18
    Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia. 1999; 13: 14811490.
  • 19
    Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 13121320.
  • 20
    Johnson P, Hunt L, Liu Yin J. Prognostic factors in elderly patients with acute myeloid leukemia: development of a model to predict survival. Br J Haematol. 1993; 85: 300306.
  • 21
    Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukemia in the elderly: retrospective study of 235 patients. Br J Haematol. 1994; 86: 8291.
  • 22
    Wahlin A, Markevärn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 2001; 115: 25.
  • 23
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997; 89: 33233329.
  • 24
    Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999; 17: 28192830.
  • 25
    Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997; 90: 29692977.
  • 26
    Estey E, Thall P, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999; 93: 24782484.
  • 27
    Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 2001; 92: 19992015.
  • 28
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 29
    Cox D. Regression models and life tables. J Stat Soc (B). 1972; 34: 187220.
  • 30
    Grambsch P, Therneau T. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515526.
  • 31
    Cox D. Logistic regression for binary response variables. In: Analysis of binary data. London: Chapman & Hall, 1989: 3343.
  • 32
    Menzin J, Lang K, Earle C, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162: 15971603.